The immune response to disease is dynamic and complex. While most companies focus on a single aspect of immunity, CytoImmune Therapeutics takes a different approach.

We’ve developed a coordinated immunotherapy platform that combines the most innovative technology – chimeric antigen receptors (CARs) and bispecific antibodies (biAbs) – with the most powerful immune cell types – T cells and natural killer (NK) cells – to expedite and personalize patient care.

PRODUCT CANDIDATE TECHNOLOGY Coalescent™ Platform Cell Type Target/Indication Preclinical IND Submitted Phase I
FLT3 CAR Lentivirus No T FLT3/AML Completed No March 2020
EGFR CAR Retro or Lentivirus No NK EGFR GBM Ongoing No No
CS1 BiAb-BCMA CAR Lentivirus Yes T CS1/BCMA MM Ongoing No March 2020

AML – acute myeloid leukemia; GMB – glioblastoma; MM – multiple myeloma